share_log

石四药集团(02005.HK)与君圣泰医药就共同研发订立框架协议

SSY GROUP (02005.HK) has signed a framework agreement with Junshentai Pharmaceutical for joint research and development.

Gelonghui Finance ·  03:35

Gelonghui, December 19, 丨 Shijiazhuang Pharmaceutical Group (02005.HK) announced that Shijiazhuang Siyao Co., Ltd. (a wholly-owned subsidiary of the company) has signed a strategic cooperation framework agreement with the wholly-owned subsidiary (“partner”) of HIGHTIDE-B (02511.HK) to combine the Group's rich experience in active screening, formulation development, transformation of results, quality and cost control, as well as Junshengtai Pharmaceutical's unique advantages in multi-system collaborative innovation of natural products to jointly overcome industry difficulties and provide breakthroughs in the fields of chronic metabolic disease, longevity and anti-aging Solution.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment